Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 129

Similar articles for PubMed (Select 24388678)

1.

Clinical observations on enzyme replacement therapy in patients with Fabry disease and the switch from agalsidase beta to agalsidase alfa.

Lin HY, Huang YH, Liao HC, Liu HC, Hsu TR, Shen CI, Li ST, Li CF, Lee LH, Lee PC, Huang CK, Chiang CC, Lin SP, Niu DM.

J Chin Med Assoc. 2014 Apr;77(4):190-7. doi: 10.1016/j.jcma.2013.11.006. Epub 2013 Dec 30.

PMID:
24388678
3.

Effects of switching from agalsidase Beta to agalsidase alfa in 10 patients with anderson-fabry disease.

Pisani A, Spinelli L, Visciano B, Capuano I, Sabbatini M, Riccio E, Messalli G, Imbriaco M.

JIMD Rep. 2013;9:41-8. doi: 10.1007/8904_2012_177. Epub 2012 Oct 21.

4.

Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal).

Tsuboi K, Yamamoto H.

Genet Med. 2012 Sep;14(9):779-86. doi: 10.1038/gim.2012.39. Epub 2012 Apr 12. Erratum in: Genet Med. 2012 Aug;14(8):762.

5.

Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal).

Tsuboi K, Yamamoto H.

Genet Med. 2012 Sep;14(9):779-86. doi: 10.1038/gim.2012.81. Epub 2012 Aug 9.

PMID:
22878505
6.

Agalsidase alfa: a review of its use in the management of Fabry disease.

Keating GM.

BioDrugs. 2012 Oct 1;26(5):335-54. doi: 10.2165/11209690-000000000-00000. Review.

PMID:
22946754
7.

Effects of enzyme replacement therapy for cardiac-type Fabry patients with a Chinese hotspot late-onset Fabry mutation (IVS4+919G>A).

Lin HY, Liu HC, Huang YH, Liao HC, Hsu TR, Shen CI, Li ST, Li CF, Lee LH, Lee PC, Huang CK, Chiang CC, Lin CY, Lin SP, Niu DM.

BMJ Open. 2013 Jul 16;3(7). pii: e003146. doi: 10.1136/bmjopen-2013-003146. Print 2013.

8.

Agalsidase alfa in pediatric patients with Fabry disease: a 6.5-year open-label follow-up study.

Schiffmann R, Pastores GM, Lien YH, Castaneda V, Chang P, Martin R, Wijatyk A.

Orphanet J Rare Dis. 2014 Nov 26;9:169. doi: 10.1186/s13023-014-0169-6.

9.

[The switch of enzyme therapy in Fabry disease].

Riccio E, Pisani A.

G Ital Nefrol. 2014 Jul-Aug;31(4). pii: gin/31.4.3. Italian.

PMID:
25098458
10.

Kidney function and 24-hour proteinuria in patients with Fabry disease during 36 months of agalsidase alfa enzyme replacement therapy: a Brazilian experience.

Thofehrn S, Netto C, Cecchin C, Burin M, Matte U, Brustolin S, Nunes AC, Coelho J, Tsao M, Jardim L, Giugliani R, Barros EJ.

Ren Fail. 2009;31(9):773-8. doi: 10.3109/08860220903150296.

PMID:
19925283
11.

Patients with Fabry disease after enzyme replacement therapy dose reduction versus treatment switch.

Weidemann F, Krämer J, Duning T, Lenders M, Canaan-Kühl S, Krebs A, Guerrero González H, Sommer C, Üçeyler N, Niemann M, Störk S, Schelleckes M, Reiermann S, Stypmann J, Brand SM, Wanner C, Brand E.

J Am Soc Nephrol. 2014 Apr;25(4):837-49. doi: 10.1681/ASN.2013060585. Epub 2014 Feb 20.

12.

Effect of agalsidase alfa replacement therapy on Fabry disease-related hypertrophic cardiomyopathy: a 12- to 36-month, retrospective, blinded echocardiographic pooled analysis.

Kampmann C, Linhart A, Devereux RB, Schiffmann R.

Clin Ther. 2009 Sep;31(9):1966-76. doi: 10.1016/j.clinthera.2009.09.008.

PMID:
19843486
13.

Effect of reduced agalsidase Beta dosage in fabry patients: the Australian experience.

Ghali J, Nicholls K, Denaro C, Sillence D, Chapman I, Goldblatt J, Thomas M, Fletcher J; Australian State Fabry Disease Treatment Centres.

JIMD Rep. 2012;3:33-43. doi: 10.1007/8904_2011_44. Epub 2011 Sep 15.

14.

[Fabry disease in Spain: first analysis of the response to enzyme replacement therapy].

Rivera Gallego A, López Rodríguez M, Barbado Hernández FJ, Barba Romero MA, García de Lorenzo Y Mateos A, Pintos Morelle G; Grupo Español de Estudio de Fabry Outcome Survey.

Med Clin (Barc). 2006 Oct 7;127(13):481-4. Spanish.

PMID:
17043001
15.

Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients.

Smid BE, Rombach SM, Aerts JM, Kuiper S, Mirzaian M, Overkleeft HS, Poorthuis BJ, Hollak CE, Groener JE, Linthorst GE.

Orphanet J Rare Dis. 2011 Oct 31;6:69. doi: 10.1186/1750-1172-6-69.

16.

Fabry disease: overall effects of agalsidase alfa treatment.

Beck M, Ricci R, Widmer U, Dehout F, de Lorenzo AG, Kampmann C, Linhart A, Sunder-Plassmann G, Houge G, Ramaswami U, Gal A, Mehta A.

Eur J Clin Invest. 2004 Dec;34(12):838-44.

PMID:
15606727
17.

Enzyme replacement therapy in two Japanese siblings with Fabry disease, and its effectiveness on angiokeratoma and neuropathic pain.

Furujo M, Kubo T, Kobayashi M, Ohashi T.

Mol Genet Metab. 2013 Nov;110(3):405-10. doi: 10.1016/j.ymgme.2013.07.005. Epub 2013 Jul 14.

PMID:
23906479
18.

Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg.

Vedder AC, Linthorst GE, Houge G, Groener JE, Ormel EE, Bouma BJ, Aerts JM, Hirth A, Hollak CE.

PLoS One. 2007 Jul 11;2(7):e598.

19.

Agalsidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in Italy.

Mignani R, Feriozzi S, Pisani A, Cioni A, Comotti C, Cossu M, Foschi A, Giudicissi A, Gotti E, Lozupone VA, Marchini F, Martinelli F, Bianco F, Panichi V, Procaccini DA, Ragazzoni E, Serra A, Soliani F, Spinelli L, Torti G, Veroux M, Cianciaruso B, Cagnoli L.

Nephrol Dial Transplant. 2008 May;23(5):1628-35. Epub 2007 Dec 5.

20.

Enzyme replacement therapy for Fabry disease: a systematic review of available evidence.

Schaefer RM, Tylki-Szymańska A, Hilz MJ.

Drugs. 2009 Nov 12;69(16):2179-205. doi: 10.2165/11318300-000000000-00000. Review.

PMID:
19852524
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk